In sum, while mechanistic plausibility is strong and extrapolation from prostate oncology supports the concept of therapeuticwindow expansion, there is presently no highlevel randomized evidence in cervical/gynecologic oncology showing hydrogels expand the therapeutic window (i.e., allowing higher tumor dose or less toxicity at equivalent tumor dose)
You can read the abstract of this article at LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial PubMed (nih.gov)
Nutrients (2018) 10(9):1220
Clinical trial participation offers a path to access Retatrutide at no cost while contributing to the research that will eventually bring it to market
2025: Novo Nordisk announced positive Phase 3 ESSENCE trial results for semaglutide in early Alzheimer's disease, reporting statistically significant slowing of cognitive and functional decline a breakthrough data package that could establish GLP-1 therapy as a neuroprotective agent and open an addressable market of 6.5 million Alzheimer's patients in the U.S
Double staining of TGF-2 and p-c-MET allowed the classification of the tumor specimens into four groups (Fig